From working on exciting client projects to attending industry events across the globe, it’s been another super busy but rewarding year here at Platelet Services HQ. In this end of year round-up, we discuss some of the highlights of our year and look ahead at what’s in store for us in 2025.
Our technical blog series: the history of anti-platelet drugs
Crafted by our non-executive director and drug discovery advisor Bob Humphries, we published a series of blogs this year running through the history of antiplatelet therapies, the advancements made and how this will affect treatments in the future.
The series began in April where we noted the 50 years that have passed since the first randomised, controlled trial of aspirin in the secondary prevention of mortality from myocardial infarction. The blog reflects on the half-century of evolution in oral antiplatelet therapy and what the future might bring.
We followed this with a blog on intravenous antiplatelet therapy looking at the comparison between oral and intravenous treatments. Then, in our most recent instalment, we looked at platelet function testing and how requirements for it have shifted through the years.
Stay tuned as we have one more blog in the works to finish off the series.
Sharing our career journeys
This year, we sat down Bob and our CEO Natalia Dovlatova to take a look at their career journeys and how they found themselves at Platelet Services.
From a medical degree and PhD in Cardiovascular Medicine to founding a platelet contract research company, find out more about Natalia’s career journey here.
Space race inspiration, a placement year at Boots and the discovery and early clinical progression of P2Y12 antagonists are just some of the highlights of Bob’s career journey. Read more about it here.
From Aberdeen to Austin
Throughout the year, we actively engaged with the global scientific community by attending and contributing to several events and conferences across the globe.
- We started the year with the Platelet Society Meeting where we sponsored and exhibited at the event in Aberdeen. You can read our takeaways here.
- At EUROTOX 2024 in Copenhagen, we explored the latest in toxicology research, connecting with thought leaders and researchers.
- The 45th Annual Meeting of the American College of Toxicology (ACT) in Austin, Texas, provided another valuable opportunity to share insights and collaborate on innovations in safety assessment.
- Closing the year, we participated in Pharmacology 2024, engaging in discussions on cutting-edge pharmacological studies.
Attending each event underscored our commitment to advancing scientific discovery and fostering collaboration in the toxicology and pharmacology fields.
Looking to the future
2024 has been another successful year for the Platelet Services team and 2025 holds lots of exciting ventures, including a return to some of our favourite annual events like ACT and the Platelet Society meeting, as well as some new events, plans for expanding our service offering and a new blog series focused on pharmacology.
We would like to extend a thank you to our clients, contacts, and friends who have supported us throughout 2024. We look forward to catching up with you in 2025.
If you think we could provide support to any of your drug discovery projects, please don’t hesitate to get in touch with our friendly team.
